Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40

被引:6
作者
Ruybal, Paula [1 ]
Gravisaco, Maria Jose [1 ]
Barcalab, Virna [2 ]
Escalada, Ana [3 ]
Di Sciullo, Paula [1 ]
Waldnera, Claudia [1 ]
Mongini, Claudia [1 ]
机构
[1] Univ Buenos Aires, Fac Med, CEFyBO CONICET, Cellular & Mol Immunol Lab, RA-1121 Buenos Aires, DF, Argentina
[2] CITOMLAB, Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[3] CITOMED, Buenos Aires, DF, Argentina
关键词
costimulatory molecules; T-cell lymphoma; gene therapy; CD40; CD80; CD40L;
D O I
10.1016/j.vaccine.2007.11.041
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The equal importance of the qualitative and quantitative characteristics of antigen presentation as well as the set of costimulatory signals provided by antigen presenting cells to T-cells in determining the outcome of T-cell responses at the time of antigen recognition is now clear. Moreover, an important function in innate mechanisms has been recently attributed to costimulatory molecules demonstrating their relevant role in different stages of immune response. In this paper, we demonstrated the ability of CD40L (CD154) and CD80 costimulatory molecules expression in a T-cell lymphoma to induce both T-cell dependent and independent immune responses leading to an important anti-tumor effect. CD40 expression by LBC cells enhanced only T-cell dependent anti-tumor immune response resulting in tumor rejection. Furthermore, this work represents the first report to describe complete tumor rejection after co-inoculation of lymphoma cells transfected with CD40L and CD80 in either presence or absence of CD40 expressing lymphoma cells. In addition, this synergistic effect resulted in long tasting immunity to parental tumor cells. Co-inoculation of tumor cells each genetically modified to express a different costimulatory molecule circumvents the need to co-transfect genetically unstable tumor cells and represents an option for those weakly or non-immunogenic tumors where either treatment atone proved to be inefficient. This strategy represents a promising approach for inducing anti-tumor immunity and provides a new rational design of cancer therapies. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:697 / 705
页数:9
相关论文
共 41 条
  • [1] Role for CD40-CD40 ligand interactions in the immune response to solid tumours
    Alexandroff, AB
    Jackson, AM
    Paterson, T
    Haley, JL
    Ross, JA
    Longo, DL
    Murphy, WJ
    James, K
    Taub, DD
    [J]. MOLECULAR IMMUNOLOGY, 2000, 37 (09) : 515 - 526
  • [2] Help for cytotoxic-T-cell responses is mediated by CD40 signalling
    Bennett, SRM
    Carbone, FR
    Karamalis, F
    Flavell, RA
    Miller, JFAP
    Heath, WR
    [J]. NATURE, 1998, 393 (6684) : 478 - 480
  • [3] Bluestone JA, 1997, J IMMUNOL, V158, P1989
  • [4] CD40 ligation activates murine macrophages via an IFN-γ-dependent mechanism resulting in tumor cell destruction in vitro
    Buhtoiarov, IN
    Lum, H
    Berke, G
    Paulnock, DM
    Sondel, PM
    Rakhmilevich, AL
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (10) : 6013 - 6022
  • [5] Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers
    Capozzo, AVE
    Cuberos, L
    Levine, MM
    Pasetti, MF
    [J]. INFECTION AND IMMUNITY, 2004, 72 (08) : 4637 - 4646
  • [6] Immunological ignorance of silent antigens as an explanation of tumor evasion
    Chen, LP
    [J]. IMMUNOLOGY TODAY, 1998, 19 (01): : 27 - 30
  • [7] The mechanism of activation of NK-cell IFN-γ production by ligation of CD28
    Cheung, JC
    Koh, CY
    Gordon, BE
    Wilder, JA
    Yuan, D
    [J]. MOLECULAR IMMUNOLOGY, 1999, 36 (06) : 361 - 372
  • [8] Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours
    Chong, H
    Hutchinson, G
    Hart, IR
    Vile, RG
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (08) : 1043 - 1050
  • [9] What is the real role of CD40 in cancer immunotherapy?
    Costello, RT
    Gastaut, JA
    Olive, D
    [J]. IMMUNOLOGY TODAY, 1999, 20 (11): : 488 - 493
  • [10] Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: A model for immunotherapy
    Dotti, G
    Savoldo, B
    Takahashi, S
    Goltsova, T
    Brown, M
    Rill, D
    Rooney, C
    Brenner, M
    [J]. EXPERIMENTAL HEMATOLOGY, 2001, 29 (08) : 952 - 961